Latest Commercialisation News

Yojee Limited has successfully raised $5.4 million through an oversubscribed placement, fueling development of its MOSAIC freight forwarding platform and expansion across the Asia Pacific region.

Vitasora Health has secured approximately A$11 million in capital to accelerate its expansion in the US remote patient monitoring market, highlighted by an upgraded contract with TPAC covering 15,000 patients. The company targets a USD 18 million annual recurring revenue run-rate by late 2026.

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Pancontinental Energy’s latest technical update reveals promising hydrocarbon potential in the PEL 87 offshore Namibia project, supported by advanced seismic and basin modelling studies. These findings set the stage for revised resource estimates later this month.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Ark Mines has awarded a contract for a 2,500m drilling campaign at its Sandy Mitchell project, aiming to significantly expand its rare earth mineral resource ahead of a key feasibility study.

Wide Open Agriculture Limited reminds shareholders of the imminent closing of its Securities Purchase Plan, offering shares at a discounted price with free options, while gearing up for an investor webinar to discuss company progress.

Kinetiko Energy has signed a non-binding term sheet with FFS Refiners to co-develop a pilot LNG plant at Brakfontein, aiming to fast-track gas production and supply to South Africa's industrial market.

Critica Limited has appointed Jacob Deysel as CEO to accelerate development of its Jupiter Rare Earth Project, signalling a strategic shift from exploration to production readiness. Deysel’s extensive global mining experience and rare earths expertise position the company for its next growth phase.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.